NSBCC: NanoSystems Biology Cancer Center - Organizations

California Institute of Technology

Tue, 17 Jan 2006 12:43:28 -0800

The mission of the California Institute of Technology is to expand human knowledge and benefit society through research integrated with education. We investigate the most challenging, fundamental problems in science and technology in a singularly collegial, interdisciplinary atmosphere, while educating outstanding students to become creative members of society.

PETNET Solutions

Mon, 23 Jan 2006 10:25:18 -0800

PETNET® Pharmaceuticals, Inc., headquartered in Knoxville, Tennessee, is the nation's leading provider of molecular tracers for PET imaging. PETNET® offers the only cyclotron-based nationwide network of radiopharmacies that produce and distribute MetaTrace FDG® and other probes to hospitals, clinics, and provider centers.

Liquidia Technologies

Mon, 23 Jan 2006 10:09:53 -0800

Liquidia Technologies provides an enabling material platform: innovative fluoropolymers that are liquids at room temperature, but cure to crystal clear "PTFE-like" elastic solids when exposed to light for a few minutes. The resulting material combines the appealing properties of silicone elastomers and glass – outperforming each, individually – and makes revolutionary applications possible. Liquidia's products will be solvent- and chemically resistant microfluidics and high performance imprint lithographic materials and processes.

Pacific Northwest Prostate Cancer Research SPORE

Mon, 23 Jan 2006 09:16:09 -0800

The Pacific Northwest Prostate Cancer Research SPORE will involve more than 50 investigators in Seattle and Vancouver, B.C.

Pacific Ovarian SPORE

Mon, 23 Jan 2006 09:12:48 -0800

The POCRC is a community-based, multidisciplinary, translational research program that involves clinicians, laboratory scientists and public health scientists from several research and medical institutions in the region. The broad based approach takes full advantage of the scientific expertise available locally and allows for the pooling of clinical resources, thus facilitating population-based studies despite the low incidence of ovarian cancer

UCLA SPORE in Prostate Cancer

Mon, 23 Jan 2006 08:58:02 -0800

The purpose of the UCLA SPORE in Prostate Cancer is to contribute significantly to progress in the diagnosis, prevention, and treatment of prostate cancer. These goals will be accomplished through multiple and diverse research projects, both in basic science and population-based research, which can be rapidly translated into clinical applications.

Siemens USA

Thu, 19 Jan 2006 11:09:24 -0800

http://www.usa.siemens.com/index.jsp

Homestead Clinical Corporation

Thu, 19 Jan 2006 11:02:35 -0800

Homestead was founded to commercialize a suite of technologies developed at the Institute for Systems Biology (ISB) that have broad utility in the development of novel diagnostic tools. The ISB is a world-renowned non- profit research institute whose mission is to unravel the mysteries of diseases such as cancer, diabetes and AIDS. Homestead will utilize proprietary technologies, licensed from the ISB, to develop diagnostic tools, designed to facilitate early intervention in a variety of diseases.

Materia

Thu, 19 Jan 2006 10:25:25 -0800

Materia Incorporated is a leader in developing and commercializing solutions to complex problems in Life Sciences, Polymers and Materials Science, and Chemical Manufacturing. The company practices innovative and proprietary Metathesis and Organocatalysis™ Technologies to provide sustainable cost advantages in the production of small, medium, and large molecules while simultaneously enabling previously unattainable features, qualities, and substances to be obtained.

The National Cancer Institute

Tue, 17 Jan 2006 20:33:33 -0800

The National Cancer Institute (NCI) is a component of the National Institutes of Health (NIH), one of eight agencies that compose the Public Health Service (PHS) in the Department of Health and Human Services (DHHS). The NCI, established under the National Cancer Act of 1937, is the Federal Government's principal agency for cancer research and training. The National Cancer Act of 1971 broadened the scope and responsibilities of the NCI and created the National Cancer Program. Over the years, legislative amendments have maintained the NCI authorities and responsibilities and added new information dissemination mandates as well as a requirement to assess the incorporation of state-of-the-art cancer treatments into clinical practice.

UCLA's Jonsson Comprehensive Cancer Center

Tue, 17 Jan 2006 20:30:00 -0800

Today, UCLA´s Jonsson Comprehensive Cancer Center (JCCC) has established an international reputation for developing new cancer therapies, providing the best in experimental and traditional treatments, and expertly guiding and training the next generation of medical researchers. With a membership of more than 230 physicians and scientists, the Jonsson Cancer Center handles more than 20,000 patient visits per year and conducts hundreds of clinical trials, providing the latest in experimental cancer treatments.

Institute for Systems Biology

Tue, 17 Jan 2006 12:42:55 -0800

The Institute for Systems Biology was co-founded in 2000 by Alan Aderem, Ruedi Aebersold, and Leroy Hood. In just five years it has grown to more than 170 staff members, including 11 faculty members and their laboratory groups. This pioneering approach to the study of biological systems takes place in the institute's 65,000-square-foot facility in Seattle.

UCLA Geffen School of Medicine

Tue, 17 Jan 2006 12:42:03 -0800